Intravenous immunoglobulins for treatment of severe COVID-19-related acute encephalopathy
Huo S, Ferse C, Bösl F, Reincke S, Enghard P, Hinrichs C, Treskatsch S, Angermair S, Eckardt K, Audebert H, Ploner C, Endres M, Prüss H, Franke C, Scheibe F. Intravenous immunoglobulins for treatment of severe COVID-19-related acute encephalopathy. Journal Of Neurology 2022, 269: 4013-4020. PMID: 35538168, PMCID: PMC9089297, DOI: 10.1007/s00415-022-11152-5.Peer-Reviewed Original ResearchSARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
Reincke S, Yuan M, Kornau H, Corman V, van Hoof S, Sánchez-Sendin E, Ramberger M, Yu W, Hua Y, Tien H, Schmidt M, Schwarz T, Jeworowski L, Brandl S, Rasmussen H, Homeyer M, Stöffler L, Barner M, Kunkel D, Huo S, Horler J, von Wardenburg N, Kroidl I, Eser T, Wieser A, Geldmacher C, Hoelscher M, Gänzer H, Weiss G, Schmitz D, Drosten C, Prüss H, Wilson I, Kreye J. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science 2022, 375: eabm5835. PMID: 35076281, PMCID: PMC8939768, DOI: 10.1126/science.abm5835.Peer-Reviewed Original ResearchConceptsCross-reactive antibodiesReceptor-binding domain antibodiesMajor antibody classCOVID-19 patientsSARS-CoV-2Next-generation vaccinesInfection elicitsVaccinated individualsAntibody responseAntibody classAntigenic driftWild-type virusPatientsBeta variantAntibodiesClonotypesDomain antibodiesVaccineMutationsSerum
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply